Alex MacKenzie

Senior Scientist, CHEO Research Institute

Alex MacKenzie is an attending pediatrician at the Children’s Hospital of Eastern Ontario(CHEO) in Ottawa, Canada and has served as the CEO and Science Director of the CHEOResearch Institute as well as Vice President of Research for both CHEO and Canada’s federalgenomic research funding agency, Genome Canada. In addition to being a founding scientist ofthe AeGera biotech company, Dr. MacKenzie’s laboratory has conducted translational researchon the rare pediatric disorder spinal muscular atrophy over the past 25 years; in recent years ithas broadened its focus through the enhanced Care for Rare project to search for therapies for alarger number of rare genetic diseases.

Related News

Research Projects

  1. The role of wastewater testing for SARS-CoV-2 surveillance


    These characteristics of SARS-CoV-2 infection, along with the observation that SARSCoV-2 is excreted in stools during all phases of infection, has led to the uptake of wastewater testing to complement SARS-CoV-2 surveillance based on clinical tests and case identification.

  2. Core Outcome Sets for Medium-Chain Acyl-CoA Dehydrogenase Deficiency and Phenylketonuria


    Adoption in future studies will help to ensure best use of limited research resources to ultimately improve care for children with these rare diseases.

  3. Catching a resurgence: Increase in SARS-CoV-2 viral RNA identified in wastewater 48 hours before COVID-19 clinical tests and 96 hours before hospitalizations


    Wastewater-based COVID-19 epidemiology programs have been initiated in many countries to provide public health agencies with a complementary disease tracking metric and non-discriminating surveillance tool.

  4. Newborn Screening for Spinal Muscular Atrophy: Ontario Testing and Follow-up Recommendations


    The goal is to provide timely access to those SMA infants in need of therapy to optimize motor function and prolong survival.

  5. SARS-CoV-2 Protein in Wastewater Mirrors COVID-19 Prevalence


    Here, we demonstrate the presence of SARS-CoV-2 structural proteins in wastewater using traditional immunoblotting and quantitate them from wastewater solids using an immuno-linked PCR method called Multiplex Paired-antibody Amplified Detection (MPAD). In this longitudinal study, we corrected for stochastic variability inherent to wastewater-based epidemiology using multiple fecal content protein biomarkers.